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Abstract: This paper raises some troubling questions about the fertility treatments provided to Canadian
gestational surrogates, women not genetically related to the child that they carry. Using information
published between 2003 and 2012 by Canada’s Assisted Reproduction Registry, the paper traces the growing
incidence of births to gestational surrogates. The transfer of more than one embryo increases the chance of
pregnancy and the incidence of multiple births, and while the incidence of multiple births has declined
overall since 2010, gestational surrogates consistently experience a higher proportion of multiple births and
experienced higher levels of multiple embryo transfers. In 2012, just 26% of gestational surrogates received a
single embryo transfer compared to 47% of other in vitro fertilisation (IVF) patients. The paper suggests that
renewed attention needs to be paid to the counselling provided to gestational surrogates and treatment
consenting mechanisms used by IVF clinics and that review of the 2007 Canadian Medical Association surrogate
treatment guidelines is warranted. Finally, the paper describes the difﬁculties in obtaining accurate data about
Canadian assisted reproductive medicine. Without good data, it becomes far more difﬁcult to identify the pos-
sibility of potentially harmful practices. © 2016 Reproductive Health Matters. Published by Elsevier BV. All
rights reserved.
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Introduction
The practice of a woman conceiving and carrying a
child for an individual or couple, who for medical
or social reasons are unable to have their own
children, has been characterized as morally trou-
bling as it breaks the assumed closed link between
genetics, gestation, and motherhood.1,2 The dis-
course and practice of surrogacy raises tensions
about contracts, altruism, autonomy, and inde-
pendence and about its potential to commercia-
lise human reproduction and commoditise the
body.3–5
In Canada, both ‘traditional’ surrogacy, where the
surrogate is genetically related to the child she bears
for the intended parent(s), and ‘gestational’ surro-
gacy, where the surrogate has no genetic link to the
offspring, are lawful provided that the surrogate
arrangement is altruistic, though expenses incurred
by the surrogate can be reimbursed.6 For an increas-
ing number of childless Canadian couples and indivi-
duals including gay men, surrogacy may be the only
way to have biological children. A 2012 survey reveals
that surrogacy is neither a taboo topic nor an unrea-
listic reproductive option for many Canadians; one-
quarter of childless adult women and 40% of child-
less adult men would consider using a surrogate
should they or their partner not be able to carry
and give birth to their biological child.7 Personal tes-
timonials featured in popular magazines,8–10 news-
paper articles reporting on out-of-province and out-
of-country surrogate births,11–13 and exposés of
media celebrities including Joël Legendre and his
husband, who forced the Quebec government to
pay their surrogacy costs,14 lead one to conclude that
surrogacy as practiced in Canada is an acknowledged,
albeit controversial, twenty-ﬁrst century family-
making activity.
Despite Canadians’ increased acceptance of
surrogacy, comparatively little is known about the
practice. Lack of data,15 social stigma associated
with infertility,16 perception of legal uncertainty
about surrogacy,15–17 and reproductive tourism18,19
have been cited as factors contributing to a shortage
of reliable and comprehensive information about
Canada’s surrogacy practices.
This paper seeks to ﬁll this knowledge gap, and
in so doing, it raises several troubling questions
about the fertility treatments gestational surro-
gates receive. While there are limitations with
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the data source – the Canadian Assisted Reproduc-
tion Technology Registry (CARTR) and Better
Outcomes Registry and Network (BORN) – used to
analyse gestational surrogacy trends and out-
comes, the paper demonstrates that assisted
reproduction technology (ART) registry informa-
tion yields important insights.
Canada’s Assisted Reproduction Technology
Registry: CARTR-BORN
The science of embryology, the practice of repro-
ductive medicine, and the regulation of fertility
treatment data collection systems play pivotal
roles in the structure of ART registries and the
management of fertility treatment knowledge.20
These factors shape the medicalised narrative
structuring what “we know and do not know”21
about fertility treatment in general and surrogacy
in particular.
Unlike their American22 and British23 counter-
parts, Canadian fertility clinics are not required
by law to report AR treatment information to a
recognised public health authority. When Canada’s
Assisted Human Reproduction (AHR) Act 2004 was
passed, CARTR, as it was then known, could have
been replaced or possibly merged into the feder-
ally legislated Personal Health Information Regis-
try, but it was not. The 2010 Reference re AHR Act
decision24 ended the federal government’s ability
to establish ART and donor registries when the
Supreme Court of Canada ruled ultra vires the
sections of the Act regulating areas deemed to be
under provincial constitutional authority, namely
the practice of medicine and research. In 2010
Quebec regulated the practice of fertility medi-
cine25 and by early 2016, Ontario was funding
one stimulated cycle of IVF.26 To date, no provin-
cial government has created fertility treatment or
donor registries, though the Canadian Fertility and
Andrology Society (CFAS) recently recommended
the creation of a national donor registry.27
CARTR-BORN, a voluntary ART registry estab-
lished and governed by Canada’s IVF clinic directors
since 1999, functions as the country’s principle
source of information on IVF medical practices.
Regarding surrogacy, the registry contains data on
the IVF treatments provided to gestational surro-
gates deﬁned as:
“A woman who carries a pregnancy with an agree-
ment that she will give the offspring to the intended
parent(s). Gametes can originate from the intended
parent(s) and/or a third party (parties).” 28
In instances of conception occurring as a result of
donor insemination, a practicemore typical of tradi-
tional surrogacy, the registry does not record this
type of information. While IVF could be performed
on traditional surrogates, Canadian fertility clinics
like their American counterparts offer IVF services
to gestational surrogates,30 thus, Canadian and
American ART registries shed no light on traditional
surrogacy practices. In contrast the UK Human Fer-
tilisation and Embryology Authority (HFEA) records
fertility treatments provided to both traditional
(genetic) and gestational surrogates but does not
routinely publish this information.31
CARTR-BORN presents a national picture of IVF
treatments provided to gestational surrogates, how-
ever, its focus and structure contribute to data
limitations. It holds no socio-economic information
or information on fertility treatments undertaken
outside Canada, and little demographic data on
patients. Yet, it could tell us about the use of
Canadian IVF clinics by non-residents as the address
of patients and intended parents is collected,
though not all clinics consistently submit this infor-
mation to CARTR-BORN.32
The organisation of fertility treatment informa-
tion by IVF cycle* reﬂects embryological and ART
medical practices, telling us more about gametes,
embryos, and fertility procedures than about
the patients receiving treatment.20,36 However,
by analysing this information over time, the emer-
ging picture of gestational surrogacy practices
reveals important differences in fertility treat-
ments provided to surrogate compared to non-
surrogate mothers.
Methods
Between 2001 and 2007, Canada’s ART treatment
statistics were published in the journal Fertility
and Sterility. From 2008 to 2012, annual data
reports were made available to CFAS members
and disseminated via the organisation’s website.37
Beginning in 2013, only media overviews have
been released. Customised tabulations are made
available to approved researchers by BORN, the
organization now hosting the registry on behalf
of IVF clinic directors.28
*A treatment cycle is considered to have “started” when a
woman undergoing ovarian stimulation receives the ﬁrst dose
of gonadotropins or, in a non-stimulated cycle (e.g., for Frozen
Embryo Transfer (FET)), when monitoring is begun.
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In response to a need for information on
Canadian surrogacy practices,16–18,37 the paper
calculates the incidence of IVF births to gestational
surrogates for the period 2001-2012 (Table 1). It
then focuses on the period 2003-2012, during
which most clinics reported in every year and
during which important fertility treatment and
policy changes took place, including federal legis-
lation, publication of surrogate treatment and
embryo transfer guidelines, greater availability of
donor gametes (ova and sperm), regulation of fer-
tility medicine by Quebec, and increased reliance
on gestational surrogacy by childless couples and
individuals including gay men.38–40 Data for 2012
was the most recent that could be made available
by BORN. For reasons of conﬁdentiality, only
Canada-level information could be obtained.
Descriptive statistics showing the number
of gestational surrogate treatment cycles,
pregnancies, births, and incidence of multiple
births were compiled using ART treatment data
published in the CARTR-BORN annual reports
2001-2012 and from data requests. Quebec-level
data were obtained from the 2014 Quebec Com-
mission Report.41 Author-designed custom tabula-
tions were used to verify previously released
Table 1. Births in Canada, 2001-2012
2001 2002 2003 2004 2005 2006
Births 333,744 328,802 335,202 337,072 342,176 354,617












IVF births to gestational
surrogates (% of total IVF
births)
18 (0.9%) 18 (0.7%) 12 (0.7%) 20 (0.6%) 30 (0.8%) 35 (0.9%)
Number of infants born to
gestational surrogates (% of
all infants born)
21 (0.9%) 22 (0.9%) 15 (0.5%) 27 (0.8%) 38 (1.1%) 47 (1.2%)
Number of infants
born to all IVF patients
2,247 2,337 3,107 3,210 3,554 3,927
2007 2008 2009 2010 2011 2012 Total
Births 367,864 377,886 380,863 377,213 377,636 380,659* 3,959,990













IVF births to gestational
surrogates (% of total IVF births)
48 (1.1%) 59 (1.2%) 79 (1.4%) 78 (1.4%) 113 (1.8%) 113
(1.7%)
626
Number of infants born to
gestational surrogates (% of all
IVF infants)
67 (1.5%) 77 (1.5%) 113 (2.0%) 103 (1.8%) 140 (2.2%) 133
(1.9%)
803
Number of infants born to all
IVF patients
4,499 5,104 5,710 5,707 6,381 6,988 52,771
Sources: CARTR-BORN. Statistics Canada, CANSIM Tables 102-4509. Live births, by birth weight and sex, Canada, pro-
vinces and territories.
*Statistics Canada, CANSIM Table 053-0001. Estimates of live births, deaths and marriages, Canada, provinces and
territories.
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information about gestational surrogates and to
calculate statistics for the non-gestational surro-
gate population. Data showing the incidence of
one, two, and three plus embryos transferred per
gestational surrogate and other IVF patient (non-
gestational surrogate) treatment cycle were also
obtained.42 Comparative custom tabulations were
made available by the Centers for Disease Control
and Prevention (CDC) from the National ART Sur-
veillance System.43
Parametric statistics were used to calculate the
risk ratios (RR) of gestational surrogates receiving a
transfer of one embryo compared to two, and
three or more embryos.44 All tests were two-
sided and p-values of less than 0.05 were consid-
ered statistically signiﬁcant. Donor and intended
mother’s own ova and fresh and frozen embryos
were considered in the analysis.
Results
Increase in gestational surrogacy
Between 2001 and 2012, 52,488 live births were
reported to CARTR-BORN. In 2012, IVF conceived
infants comprised 1.8% of all Canadian births45 and
over 2.0% of all births occurring in Quebec.41 This
compares to 1.5% of American births34 and 2.2% of
all babies born in the UK in that year.46
A total of 803 IVF conceived infants were born to
gestational surrogates between 2001 and 2012. The
133 babies born to gestational surrogates in 2012
represented 1.9% of all IVF conceived babies born
in Canada (1.8% of all IVF cycles). In the US, the CDC
estimates gestational surrogates comprised about 2.5
percent all IVF cycles the same year33 (Table 1).
Canadian gestational surrogates were younger
than intendedmothers (IM); themedian age of gesta-
tional surrogates was 31.8 years compared with 38.2
years for IM.40 CDC data show a similar age differ-
ence: median age of 31.7 years for gestational surro-
gates compared to 36.5 years for IM.43 Between 2003
and 2009, embryos containing ova obtained from
donors other than the intended mother were used
in about one-third of gestational surrogate cycles.
However, by 2012, 52% of gestational cycles involved
embryos containing non-IM ova. In contrast donor
ova were used only in 5.5% of other IVF patient cycles
that year (Figures 1 and 2).
Gestational surrogates more likely to experience
multiple birth
It has long been known that fertility patients experi-
ence a higher number of multiple births compared
to women who do not conceive using fertility
drugs or IVF.47,48What perhaps has been less under-
stood is that gestational surrogates experience
higher levels of multiple births than other IVF
Figure 1. Gestational surrogacy cycles, pregnancies and live births, 2001-2012
Source: CARTR-BORN
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patients.33,36,49 As Figure 3 illustrates, the rate of
multiple births to Canadian non-surrogate mothers
remained at around 27-31% between 2003 and
2009. Beginning in 2010, Quebec regulated the
practice of ART medicine, and fertility clinics located
elsewhere in Canada began to adopt measures to
limit number of embryos transferred.25,41,50 By
2012, the proportion of multiple births experienced
by non-gestational surrogate patients dropped dra-
matically to just under 16% (Figure 4).
Over the same period, the proportion of multiple
births experienced by gestational surrogates
remained consistently higher such that by 2009
about 41% of all gestational surrogates gave birth
to more than baby at a time. In 2010, multiple
births for gestational surrogates began to drop and
by 2012, it had declined to 17%, about the same
level as the non-gestational surrogate women.
However, the gap between the number of surrogacy
pregnancies and number of births appears to have
widened since 2009. Pregnancy loss increased from
6.6% of surrogate pregnancies in 2009 to 19.2% by
2012.37 Another possible explanation could be
inconsistent birth outcome follow up, a known data
limitation associated with ART registries.41,48
Transfer of multiple embryos
Factors contributing to multiple births include
the number of embryos transferred per cycle, ova
donor age, use of fresh or frozen human tissues
and embryos, and age of patient.33,48 Between
2003 and 2012, Canadian gestational surrogates
experienced signiﬁcantly higher risk of receiving a
multiple embryo transfer than did other IVF patients
(risk ratio [RR]: 1.08, 95% conﬁdence interval [CI]
1.06-1.10). This occurred even though surrogates
were younger and had fewer known fertility
problems.40 They were also more likely to receive
embryos containing donor ova (non-IM ova) com-
pared to other IVF patients (Table 2).
It should be noted that by 2012, while the pro-
portion of multiple births in Canada had declined
for both surrogates and non-surrogates, 60% of
gestational surrogates received a transfer of two
embryos compared to just over 40% of other IVF
patients. Moreover, when surrogates received an
Figure 2. Gestational surrogate cycles showing ova and sperm donors, 2003-2012
Source: CARTR-BORN
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embryo containing ova from a donor other than the
IM, a situation which now comprises the majority of
all gestational surrogate transfers, 85% of surrogates
received two or more embryos per transfer cycle
(Figure 5). This result raises a troubling question
about differing medical treatments being provided
to gestational surrogates compared to other IVF
patients. It also suggests that embryo transfer guide-
lines might not have been consistently followed
when the patient was a gestational surrogate.
Discussion
During the last ﬁve years of the study period, the
number of children born to Canadian gestational sur-
rogates increased by 91.5%. For a growing number
of childless Canadians, gestational surrogacy has
become a more common reproductive option. This
ﬁnding suggests that the fraud conviction of fertility
consultant Leia Picard and continued federal failure
to regulate the reimbursement of expenses incurred
by surrogates have not served to deter childless
couples and individuals from seeking to create
families through surrogacy.51,52
While Canada’s AR registry tells us about gesta-
tional surrogacy, little is known about other surro-
gacy practices. This study lacks the insights that
would be gained by having information on surrogate
and intended parent characteristics, and foreign and
traditional surrogacy practices, nonetheless its
ﬁndings lend weight to the demands made by legal
experts,15–18,29,38,54 ethicists19,52 and intended
parents11–13 for a re-examination of the legal status
of surrogacy arrangements, revision to provincial
parentage laws, and review of federal AHR Act
surrogacy provisions.
Implications of changes to fertility treatments
provided to gestational surrogates
Over the period 2001 to 2012, IVF fertility treat-
ment delivered to gestational surrogates became
increasingly dependent on ova obtained from
donors other than the intended mother. In the
US, over 70% of gestational surrogacy cycles in
2012 involved the transfer of embryos comprised
of third party ova (other than the intended
mother).43 In Canada, this phenomenon will likely
increase given greater availability of donated
gametes, reliance on gestational surrogacy by gay
men, and the advanced age of intended mothers.
The use of donor ova in gestational surrogacy
raises two troublesome questions. The ﬁrst con-
cerns Canada’s gamete screening and testing
regimes and the second pertains to the application
of embryo transfer guidelines.
In 1996, Canada regulated the screening and
testing of human sperm used in ART treatments.55
It has been suggested that inconsistency exists in
the manner in which donor sperm is screened
and tested when used by traditional and
Figure 3. Proportion of multiple births, 2001-2012
Source: CARTR-BORN
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gestational surrogates.27 Regarding ova, to date
no screening or screening regulations have been
approved and no regulatory timetable has been
provided by Health Canada, the federal depart-
ment responsible for implementation of the
federal AHR Act. In December 2012, Canada’s IVF
clinics voluntarily adopted the Canadian Stan-
dards Association (CSA) standard Z900.2.1-12 Tis-
sues for assisted reproduction. By mid-2015, the
Standard was scheduled for review and revision.
Figure 4. Distribution of embryos transferred, 2003-2012
Source: CARTR-BORN
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In 2016, the CFAS released Third Party Reproduc-
tion guidelines which outlined sperm and ova
screening and testing procedures for surrogate
patients.27 No doubt, professional adherence to
national standards and clinical practice guide-
lines offer a measure of comfort to IVF clinic staff
and patients. However, neither the CSA standard
nor the CFAS clinical guidelines have the force of
federal law as envisaged by Parliament when
amendments to the Assisted Human Reproduc-
tion Act were passed in 2012.
Multiple embryo transfers
IVF is costly and there exist economic as well as
health care pressures to achieve success with each
fertility treatment cycle. Multiple embryo trans-
fers increase the chance of pregnancy as well as
multiple births, but giving birth to more than
one child at a time poses health risks for mothers
and children. Infant low-birth weights, early
births, and the increased incidence of stillbirths,
neonatal deaths, and birth anomalies are all asso-
ciated with multiple birth pregnancies.56,57 Ontar-
io’s Expert Panel on Infertility and Adoption
concluded that multiple birth infants are 17 times
more likely to be born pre-term, to require a cae-
sarean delivery, and to need expensive care at
birth and throughout their lives.58
Yet, as this study reveals, Canadian gestational
surrogates more frequently receive multiple
embryos and until recently were more likely to
experience multiple births compared with other
IVF patients. This ﬁnding suggests that Canadian
gestational surrogates may have been taking greater
health risks than other IVF patients. It raises funda-
mental questions regarding patient autonomy and
informed consent to medical treatment in addition
to the duties of non-maleﬁcence and beneﬁcence
owed to gestational surrogates. It also raises the
issue of whether protections should be in place to
limit the risks that surrogates may take, bearing in
mind the strong pressures, including their own
altruistic desires to assist others, that might inﬂu-
ence a surrogate to pay insufﬁcient regard to her
own health and wellbeing.
Expensive IVF payments, intended parents’
strong desire for children, twin preference, and
an underestimation of health risks47,48,59 could
be among the factors encouraging an altruistic sur-
rogate, especially someone who is a close friend,
Figure 5. Gestational Surrogate Cycles Showing Transfer of Donated (Non-Intended
Mother’s) Ova, 2003-2012
Source: CARTR-BORN
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relative, or co-worker, to acquiesce to multiple
embryo transfer. In Canada, it is estimated that
25% of gestational surrogates are family members
or friends of intended parents.40 As Ashenden
reminds us,1 social coercion experienced by surro-
gates in altruistic circumstances can be subtle and
mediated.
Given that gestational surrogates are younger
and more likely to use embryos containing ova
provided by donors younger than 35 years –
factors which increase the chance of pregnancy
and successful delivery – 33,48 it would have been
expected that surrogates would be more likely to
receive a single embryo transfer compared to
non-surrogates who tend to be older and more
often use their own ova. This has not been the
case. In 2012 for example, just 26% of gestational
surrogates received a single embryo transfer
Table 2. Population characteristics and ART treatment factors of gestational surrogate





2003-2012 2012 2003-2012 2012
No. of IVF cycles 1,955 (1.5) 377 (1.7) 131,427 (98.5) 21,522 (98.3)





























































1. Residence of patients/intended parents in-and-outside of Canada. Collected by CARTR-BORN for Ontario IVF
clinics only.
2. Gestational surrogate transfers of donor ova (non-IM ova) comprised 13.5% of all donor ova transfers between 2007-
2012. During this period, 83-91% of all donor ova was donated by women aged less than 35 years; in 2012, 89% of
donor ova used in IVF/ICSI (intracytoplasmic sperm injection) was donated by women aged less than 35 years (617
cycles) and 91% of donor ova used in frozen embryo transfers was donated by women aged less than 35 years (637
cycles). Information on age of ova donor was not consistently reported to CARTR-BORN prior to 2007.
3. Age of gestational surrogate is not collected by CARTR-BORN. Limited demographic information is collected for the
intended parent(s) only. Like the US ART registry NASS, Canada’s CARTR-BORN considers the IVF patient to be the
intended parent and not the gestational surrogate as it is the intended parent(s) who experiences infertility problems
and who seeks the fertility treatment. Information about transfers to gestational surrogates is collected, however. See
Perkins, Boulet, Jamieson et al (2016) and Dar, Lazer, Basilie et al. (2015).
Source: CARTR-BORN (Canadian Assisted Reproductive Technologies Registry and Better Outcomes Registry & Network
Ontario). Ottawa ON, November 2015.
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compared to 47% of other IVF patients. Yet, in
more than half of all transfer cycles the embryos
received by gestational surrogates contained ova
provided by non-IM donors. When donor ova are
used in fertility treatments, the age of the donor
is to be used to determine the number of embryos
to transfer.50 For example in 2012, had the
embryo transfer guidelines been followed, more
than one-half of gestational surrogate cycles
should have involved a single embryo transfer,
yet less than one-quarter did. Based on this ﬁnd-
ing, we need to question why Canada’s embryo
transfer guidelines have not been more consis-
tently applied to gestational surrogates.
In light of the ﬁndings, the CFAS 2016 Clinical
Practice Guidelines for Third Party Reproduction
should provide much needed direction and gui-
dance,27 which will hopefully lead to a revision
of the 2007 Canadian Medical Association’s advice
to physicians60 regarding duty of care responsibil-
ities for surrogates. In addition, Canada’s embryo
transfer guidelines50 should be revised to reﬂect
the recommendations made by the European
Society of Human Reproduction and Embryology
which since 2005 has called for gestational surro-
gacy IVF patients to receive one embryo, with two
embryos being transferred in special circum-
stances only.61,62 To provide needed oversight,
the CFAS ought to provide an annual reporting of
multiple births to surrogates and transfers of
embryos containing IM and non-IM ova.
Lessons for law, policy and research
These ﬁndings challenge us to look more carefully at
how fertility medicine is practiced and how it is
delivered to surrogates, a group of patients often
hidden from view and for whom the duty of care is
high. While this study examined the situation of
Canadian altruistic gestational surrogates, its ﬁndings
may have salience in other jurisdictions. In particular,
its focus on multiple embryo transfers and multiple
births could be useful in research into commercial
surrogacy practices occurring in less developed
countries where out-of-country surrogacy is becom-
ing a growing industry, an area recently identiﬁed
as constituting a signiﬁcant knowledge gap.63
This paper shows that more information exists
about Canada’s gestational surrogacy practices
than has been acknowledged. Moreover, analysis
of ART treatment trends over time can reveal
changes in fertility treatments, highlight areas of
differing medical practice, and pin-point topics
meriting further investigation. However, the data
source cannot ﬁll the longstanding data gaps
pertaining to traditional and foreign surrogacy
practices. Nor can it replace in-depth case studies
and qualitative research; research which often
adopts approaches which deviate from the medi-
cal model of family-making which for too long
has dominated our understanding of infertility
and surrogacy.3,20,40,53,64
ART-based studies have additional data limita-
tions, including timeliness.20,33,36,41 The ﬁndings
of this study are based on CARTR-BORN registry
data for the years, 2001 to 2012, hence, it has
not been possible to identify changes that may
have occurred since 2012. Also, due to conﬁden-
tiality, no provincial-level data were made avail-
able for analysis. Not knowing provincial or even
regional Canadian differences masks trends
which in the context of surrogacy are important
given differing provincial responses to the legali-
sation of parental status for intended parents29,38
and in the regulation of fertility medicine.25,26
Several other confounding factors limit study ﬁnd-
ings, including a lack of socio-economic and demo-
graphic information about surrogates and intended
parents. For example, surrogate age is not collected
by CARTR-BORN and so could not be included in the
analysis. As well, Canada’s surrogate population is
relatively small, though this limitation is evident in
other published surrogate studies63 (Table 2). In light
of these weaknesses, additional research examining
trends of multiple births and embryo transfer for
gestational surrogates should be undertaken asmore
up-to-date data become available.
In conclusion, in highlighting the growth and
changes in altruistic gestational surrogacy prac-
tices in Canada, the study reveals that Canada’s
altruistic solution to the tensions raised by surro-
gacy does not diminish the need for oversight or
for additional protections. An ironic yet particu-
larly troubling concluding observation is that
Canada’s ART legislation had been designed to
protect women and the children born as a result
of assisted reproductive techniques. This study’s
ﬁndings cast doubt on its ability to achieve these
objectives.
2013 UPDATE:
In 2013, there were 416 gestational surrogate IVF
cycles resulting in 166 pregnancies, and 116 live
births of which 28 were multiple births. Thus in
2013, the level of multiple births rose to 24.1%
reversing the trend of declining multiple births.
A total of 145 infants were born to gestational
PM White. Reproductive Health Matters 2016;24:205–217
214
surrogates in 2013 bringing the total number of
children born to gestational surrogates to 948
for the period 2001-2013.
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Résumé
Cet article soulève des questions troublantes sur
les traitements de la fécondité pratiqués sur les
mères porteuses (femmes qui ne sont pas
génétiquement apparentées à l’enfant qu’elles
portent) canadiennes. En utilisant les informations
publiées sur une période de dix ans (2003-2012)
par le Registre canadien des techniques de
procréation assistée, l’article révèle l’incidence
croissante des naissances chez des mères
porteuses. L’implantation de plus d’un embryon
augmente les chances de grossesse et l’incidence
de naissances multiples et, s’il est en général
moins fréquent qu’elles donnent naissance à plus
d’un enfant à la fois depuis 2010, les mères
porteuses enregistrent systématiquement une
proportion plus élevée de naissances multiples. En
2012, à peine 26% des mères porteuses avaient
reçu l’implantation d’un seul embryon,contre 47%
des autres patientes de la FIV. L’article suggère
qu’il faut accorder davantage d’attention aux
conseils prodigués aux mères porteuses et aux
mécanismes de consentement au traitement
utilisés par les cliniques de FIV. Il note aussi
qu’il est nécessaire de réviser les directives de
l’Association médicale canadienne sur le traitement
des mères porteuses. Enﬁn, l’article décrit les
difﬁcultés rencontrées pour obtenir des données
exactes sur la procréation médicalement assistée
au Canada. Sans informations solides, il est
beaucoup plus difﬁcile de déceler la possibilité de
pratiques potentiellement nuisibles.
Resumen
Este artículo plantea algunas preguntas preocupantes
acerca de los tratamientos de fertilidad
proporcionados a madres gestantes (mujeres que
no están emparentadas genéticamente con la
criatura que llevan en el vientre) canadienses.
Utilizando información publicada en un plazo de
diez años (de 2003 a 2012) por el Registro
Canadiense de Técnicas de Reproducción Asistida,
el artículo rastrea la creciente incidencia de partos
a madres gestantes. La transferencia de más de un
embrión aumenta la probabilidad de embarazo y
la incidencia de partos multiples y aunque la
incidencia de dar a luz a más de un hijo a la vez ha
disminuido en general desde el año 2010, las madres
gestantes experimentan un mayor porcentaje de
partos múltiples. En el año 2012, tan solo el 26% de
las madres gestantes recibieron una transferencia de
un único embrión, comparado con el 47% de otras
pacientes de fertilización in vitro (FIV). El artículo
sugiere que es necesario prestar atención renovada
a la consejería brindada a madres gestantes y a los
mecanismos utilizados por las clínicas de FIV para
obtener consentimiento para el tratamiento, y
que es necesario revisar las directrices de 2007
de la Asociación Médica Canadiense referentes al
tratamiento de madres gestantes. Por último, el
artículo describe las diﬁcultades para obtener datos
exactos sobre la medicina reproductiva asistida
canadiense. Sin datos buenos, es mucho más difícil
identiﬁcar la posibilidad de prácticas posiblemente
dañinas.
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